Literature DB >> 28696248

Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.

Daniel Granado1, Daria Müller1, Vanessa Krausel1, Etty Kruzel-Davila2, Christian Schuberth3, Melanie Eschborn4, Roland Wedlich-Söldner3, Karl Skorecki2,5, Hermann Pavenstädt1, Ulf Michgehl6, Thomas Weide6.   

Abstract

Population genetic approaches have uncovered a strong association between kidney diseases and two sequence variants of the APOL1 gene, called APOL1 risk variant G1 and variant G2, compared with the nonrisk G0 allele. However, the mechanism whereby these variants lead to disease manifestation and, in particular, whether this involves an intracellular or extracellular pool of APOL1 remains unclear. Herein, we show a predominantly intracellular localization of APOL1 G0 and the renal risk variants, which localized to membranes of the endoplasmic reticulum in podocyte cell lines. This localization did not depend on the N-terminal signal peptide that mediates APOL1 secretion into the circulation. Additionally, a fraction of these proteins localized to structures surrounding mitochondria. In vitro overexpression of G1 or G2 lacking the signal peptide inhibited cell viability, triggered phosphorylation of stress-induced kinases, increased the phosphorylation of AMP-activated protein kinase, reduced intracellular potassium levels, and reduced mitochondrial respiration rates. These findings indicate that functions at intracellular membranes, specifically those of the endoplasmic reticulum and mitochondria, are crucial factors in APOL1 renal risk variant-mediated cell injury.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  APOL1; endoplasmic reticulum; energy depletion; mitochondria; podocyte; renal risk variant

Mesh:

Substances:

Year:  2017        PMID: 28696248      PMCID: PMC5661279          DOI: 10.1681/ASN.2016111220

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  60 in total

1.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Authors:  Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

2.  KIBRA modulates directional migration of podocytes.

Authors:  Kerstin Duning; Eva-Maria Schurek; Marc Schlüter; Michael Bayer; Hans-Christian Reinhardt; Albrecht Schwab; Liliana Schaefer; Thomas Benzing; Bernhard Schermer; Moin A Saleem; Tobias B Huber; Sebastian Bachmann; Joachim Kremerskothen; Thomas Weide; Hermann Pavenstädt
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

3.  Self-organization of core Golgi material is independent of COPII-mediated endoplasmic reticulum export.

Authors:  Christian E Schuberth; Carolina Tängemo; Cvetalina Coneva; Christian Tischer; Rainer Pepperkok
Journal:  J Cell Sci       Date:  2015-02-25       Impact factor: 5.285

4.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

Review 6.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

Authors:  Barry I Freedman; Jeffrey B Kopp; Carl D Langefeld; Giulio Genovese; David J Friedman; George W Nelson; Cheryl A Winkler; Donald W Bowden; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 10.121

7.  Polycystin-2 activity is controlled by transcriptional coactivator with PDZ binding motif and PALS1-associated tight junction protein.

Authors:  Kerstin Duning; Deike Rosenbusch; Marc A Schlüter; Yuemin Tian; Karl Kunzelmann; Nina Meyer; Ulf Schulze; Arseni Markoff; Hermann Pavenstädt; Thomas Weide
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

8.  The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo.

Authors:  Kristen L Meerbrey; Guang Hu; Jessica D Kessler; Kevin Roarty; Mamie Z Li; Justin E Fang; Jason I Herschkowitz; Anna E Burrows; Alberto Ciccia; Tingting Sun; Earlene M Schmitt; Ronald J Bernardi; Xiaoyong Fu; Christopher S Bland; Thomas A Cooper; Rachel Schiff; Jeffrey M Rosen; Thomas F Westbrook; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-09       Impact factor: 11.205

Review 9.  The AMPK signalling pathway coordinates cell growth, autophagy and metabolism.

Authors:  Maria M Mihaylova; Reuben J Shaw
Journal:  Nat Cell Biol       Date:  2011-09-02       Impact factor: 28.824

10.  ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death.

Authors:  Siqin Zhaorigetu; Guanghua Wan; Ramesh Kaini; Zeyu Jiang; Chien-an A Hu
Journal:  Autophagy       Date:  2008-11-23       Impact factor: 16.016

View more
  43 in total

1.  Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Authors:  Herbert Lannon; Shrijal S Shah; Leny Dias; Daniel Blackler; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2019-08-01       Impact factor: 10.612

Review 2.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

3.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

Review 4.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

5.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

Review 6.  Mechanisms of Injury in APOL1-associated Kidney Disease.

Authors:  Lijun Ma; Jasmin Divers; Barry I Freedman
Journal:  Transplantation       Date:  2019-03       Impact factor: 4.939

7.  Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.

Authors:  Justin Chun; Jia-Yue Zhang; Maris S Wilkins; Balajikarthick Subramanian; Cristian Riella; Jose M Magraner; Seth L Alper; David J Friedman; Martin R Pollak
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-07       Impact factor: 11.205

8.  The Mechanism of Kidney Disease Due to APOL1 Risk Variants.

Authors:  Etienne Pays
Journal:  J Am Soc Nephrol       Date:  2020-09-17       Impact factor: 10.121

9.  An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.

Authors:  DengFeng Li; James A Snipes; Mariana Murea; Anthony J A Molina; Jasmin Divers; Barry I Freedman; Lijun Ma; Snezana Petrovic
Journal:  Am J Nephrol       Date:  2020-08-31       Impact factor: 3.754

10.  Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function.

Authors:  Somenath Datta; Rama Kataria; Jia-Yue Zhang; Savannah Moore; Kaitlyn Petitpas; Adam Mohamed; Nathan Zahler; Martin R Pollak; Opeyemi A Olabisi
Journal:  J Am Soc Nephrol       Date:  2020-07-16       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.